December 2016
-
FluGen has announced that preliminary data from a Phase 2 trial show that its intranasal M2SR manufactured with a strain of influenza that was used in vaccines during the 2008-2010 influenza seasons protected against a… Read more . . .
-
Pulmatrix announced that it has received five new patents covering PUR1800 and PUR5700, which are inhaled narrow spectrum kinase inhibitors that Pulmatrix licensed from Janssen subsidiary RespiVert in June 2017. The new patents include two… Read more . . .
-
Orion and Propeller Health have announced that they will co-develop a custom sensor for Orion’s Easyhaler devices that will allow the inhalers to connect to Propeller’s digital inhaler monitoring platform. According to the companies, “Development… Read more . . .
-
The FDA has cleared Pulmatrix’s investigational new drug application, giving the company the go-ahead to begin a Phase 2 clinical trial of Pulmazole (PUR1900) inhaled dry powder itraconazole for the treatment of allergic bronchopulmonary aspergillosis… Read more . . .
-
Avadel Specialty Pharmaceuticals, which marketed Noctiva desmopressin nasal spray in the US, has filed for Chapter 11 bankruptcy, parent company Avadel Pharmaceuticals announced. Less than a year after launching Noctiva in the US, Avadel said… Read more . . .
-
Glenmark Pharmaceuticals announced that it has agreed to a licensing deal giving Grandpharma exclusive rights to commercialize Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray in China. The company recently announced that Yuhan had acquired South Korean rights… Read more . . .
-
Senzer’s Systemic inhaled Delivery Device (SiDD) has won an iF Design Award in the Medicine/Health product category, the company said. The inhaler also recently won a 2018 Good Design award in the medical category. The… Read more . . .
-
AIT Therapeutics said that it has received a $3.15 million milestone payment from Circassia Pharmaceuticals after successful completion of a pre-submission meeting with the FDA for AirNOvent nitric oxide delivery system. Circassia recently announced that… Read more . . .
-
Biohaven Pharmaceutical announced the successful completion of a Phase 1 trial of its BHV-3500 intranasal calcitonin gene-related peptide (CGRP) receptor antagonist and said that the company plans to initiate a Phase 2 efficacy trial in… Read more . . .
-
Acorda Therapeutics has announced the appointment of Peter S. Carbone as Senior VP, Quality. Carbone was most recently VP of Quality Solids Americas & Special Technologies at Novartis and previously held executive positions at Amgen… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland